Adrienne MacMillan, Chief Financial Officer and Founder

  • Former CFO, Rapidscan Pharma Solutions; VP Finance, CVT

Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder

  • Former Senior Advisor, Gilead Sciences; VP Neurology Research, CVT;  Vice Chair, UCSF Department of Neurology; Founding Director, UCSF Ernest Gallo Clinic and Research Center

AMYGDALA PRESS RELEASE: Feb 16, 2017

Amygdala Neurosciences Acquires GS-6637 from Gilead

Brent Blackburn, PhD, Chief Executive Officer and Founder

  • Former CEO, Rapidscan Pharma; SVP R&D, CVT

AMYGDALA PRESS RELEASE: ​March 28, 2019

Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637​

The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.

In addition to the BOD members listed above, the BOD also includes:

Lou Lange, MD, PhD, Executive Chairman and Founder

  • General Partner Asset Management; Senior Advisor to CEO, Gilead Sciences
  • Former Founder Chairman & CEO, CV Therapeutics; Chief of Cardiology and Professor of Medicine at Jewish Hospital Washington University

The Team

NIH PRESS RELEASE: March 21, 2019

NIH to test experimental drug to curb opioid cravings

The Board of Directors

Mack Mitchell, MD, Medical Advisor

  • EVP of Health System at the University of Texas Southwestern Medical Center; former Chief of Gastroenterology and the Medical Director of Ambulatory Services at Johns Hopkins Bayview Medical Center

News

Type your paragraph here.

​MEDIA: ​NBC News, November 18, 2019

NIH Experiments With Drug to Reduce Opioid Cravings

MISSION:​              Address the Growing Unmet Need

     Associated with Substance Use Disorder

     By Discovering, Developing and Commercializing
    Safe and Effective Pharmacotherapies
    to Treat and Prevent Addiction

Based on a mechanism of action in the brain to prevent pathophysiologic dopamine surge without changes to basal dopamine (Nature Medicine 16:1024, 2010), Amygdala's ALDH2 inhibitor technology has the potential to prevent drug seeking behavior, craving and relapse. In preclinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anti-anxiety properties in models of stress.





NIH/IHV PRESS RELEASE: ​Sept 19, 2018

Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials 

William Lee, PhD, Former Executive Vice President Research, Gilead Sciences
Howard Jaffe, MD, Former CMO Gilead Sciences

Peter Strumph, CEO, Parvus Therapeutics. Former: SVP, Portola; CEO, Codexis

AMYGDALA PRESS RELEASE: ​October 17, 2019

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder​